Mallinckrodt Breached Pain Med Licensing Deal, Nuvo Says

Law360, New York (August 21, 2013, 3:41 PM EDT) -- Drug giant Mallinckrodt Inc. was sued on Tuesday by pain medication firm Nuvo Research Inc., which accuses it of jeopardizing the approval prospects of Nuvo drug Pennsaid Plus and breaching a licensing deal through "regulatory gambles" that include failing to finish necessary clinical trials. 

In a complaint filed in New York federal court, Nuvo claimed that Mallinckrodt had backed out of requirements under its licensing agreement for Nuvo's “most promising pharmaceutical asset” by failing to finish certain mandatory trials and mismanaging studies it was supposed to...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.